The Adisseo Group has exceeded the 95% shareholding threshold in the equity of Innov´ia
Adisseo Holding has today informed the board of Innov’ia that by 10 October 2011, it held more than 95% of the equity and voting rights in Innov’ia, either directly or via its G4 subsidiary, in the form of shares already in its possession or shares acquired on the market as part of the voluntary repurchase offer underway following the acquisition by Adisseo Holding of a controlling share of almost 90% of Innov’ia’s equity and voting rights.
The offer period will remain open until 31 October 2011, based on a price per share of €6.67.
With the 95% threshold of the equity and voting rights being reached, Adisseo Holding will ask Euronext Paris SA to delist the Innov’ia shares currently listed on the Marché Libre. Unless the offer is extended, this request will be submitted on 31 October 2011, the date on which the offer ends, for delisting on 7 November 2011 following the publication of an announcement by Euronext Paris SA.
Following delisting, the Innov’ia shares will be of a purely registered nature and will be recorded in an account for this purpose in a register of shareholders maintained by the company.
Adisseo Holding would like to draw the Innov’ia shareholders’ attention to the fact that due to the withdrawal of the shares from the Euronext Paris SA Marché Libre, the liquidity of the shares will be significantly reduced.
Innov’ia is one of the European leaders in the design and contract processing of powdered and granulated ingredients for the food, cosmetics, pharmaceuticals and fine chemicals industries. Unlike most other players in this sector, Innov’ia has the ability to develop new products in a very short time, while being able to manufacture them almost immediately on an industrial scale. Including its subsidiaries, Innov’ia has more than 500 listed clients, with more than 650 new products launched. Including the subsidiaries, Innov’ia has 3 production sites, 110 salaried staff and a research and development centre enabling it to carry out galenic development work. With its subsidiaries, the company quadrupled in size since 2000, achieving a consolidated turnover of approximately €16 million in 2010, currently divided as follows: the food industry (77 %), the pharmaceuticals industry (6 %), speciality chemicals (10 %) and cosmetics (7 %). Innov’ia is one of the 40 companies approved by OSEO as a recognised contractual research company and is also categorised as an “Innovative Company” eligible for the Joint Innovation Investment Fund (FCPI).